Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
On October 10, 2023, AKRO announced Efruxifermin (EFX) failed to meet the primary endpoint of fibrosis improvement at 36 weeks in the Phase 2B SYMMETRY trial in NASH patients with compensated cirrhosis. The Company’s President and CEO stated “we set a high bar with the primary endpoint after only 36 weeks of treatment.” Analysts noted that they were surprised at the 36 week miss and the study design may have stretched EFX too far.
Following this news, AKRO’s stock price fell by $30.39 per share, or approximately 63% to close at $18.15 per share.